Short-Term Debt to Equity Ratio: Grace Therapeutics (GRCE)
Grace Therapeutics, Inc. (GRCE) specializes in therapies for rare nervous system pathologies, utilizing proprietary molecules to expand into global markets. The asset value tracked on this chart currently stands at 0.00. The company attracts top biochemists through a transparent corporate culture and generous stock options. Its R&D strategy is based on adapting known compounds to accelerate FDA approval, creating an efficient pipeline of innovative drugs.
GRCE (Grace Tx): analytical breakdowns and indicator data
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Grace Therapeutics, Inc.|GRCE - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Grace Therapeutics, Inc.|GRCE - Aggregate Debt Obligations|Debts to Book Capitalization Grace Therapeutics Inc|GRCE - Company Long-Term Debts|Company Short-Term Debts Grace Therapeutics|Quick Ratio gracetx.com
- company profitability and valuation multiples indicators:
Fundamental valuation:Grace Therapeutics
Developing unique formulas to cross the blood-brain barrier requires significant capital expenditure, making liquidity control for Grace Therapeutics, Inc. (GRCE) critically important. This metric measures the ratio of short-term liabilities to equity, where reducing the share of short-term loans in equity minimizes bankruptcy risk, while the moderate use of leverage optimizes the company's overall return on assets.
Analysis of competing companies
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Short-Term Debt to Capital|DNLI - Short-Term Indebtedness to Equity|Short-Term Debt to Equity Harmony Biosciences Holdings, Inc. (HRMY)|BHVN (Biohaven Ltd) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital AMLX (Amylyx)|Short-Term Debt to Capital Trevi Corp TRVI|Praxis Precision Medicines - Short-Term Debt to Capital|anavex.com (AVXL) - Short-Term Debt to Equity Ratio|CBLL: Short-Term Debt to Capital|Current Liabilities to Capital Prothena Biosciences (PRTA)|Short-Term Debt to Equity Ratio ALEC|ANNX: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio OMER (Omeros Corporation)|Short-Term Loans to Capital Ratio NGNE|Short-Term Debt to Capital ACIU (AC Immune SA)|Ratio of Short-Term Indebtedness to Capital VYGR|Neumora Therapeutics Inc - Short-Term Debt to Capital|Current Liabilities to Capital Scilex Holding Company, Inc.|Tevogen Bio Holdings (TVGN) - Short-Term Debt to Equity|Alpha Cognition Inc. - Ratio of Short-Term Indebtedness to Capital|CGTX (Cognition Therapeutics, Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital Inhibikase Therapeutics Inc|Short-Term Debt to Equity Cassava (SAVA)|ASRT: Current Liabilities to Equity|Short-Term Debt to Capital COYA (Coya Therapeutics)|VistaGen Therapeutics, Inc. (VTGN) - Current Liabilities to Capital|OVID: Short-Term Debt to Equity Ratio|ABOS - Short-Term Debt to Capital|CRVO (CervoMed Inc) - Short-Term Debt to Equity Ratio|ATHE: Short-Term Loans to Capital Ratio|CLNN (Clene Inc) - Short-Term Debt to Capital|PepGen Corp (PEPG) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital JUNS|Short-Term Debt to Equity Ratio Relmada Therapeutics Inc RLMD|Short-Term Debt to Equity Annovis Bio Corp ANVS|Short-Term Debt to Capital Coefficient Firefly Neuro (AIFF)|KLTO: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital NRSN (NeuroSense Therapeutics)|RVPH: Short-Term Debt to Capital|MTVA - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity NeurAxis, Inc|Short-Term Debt to Capital Ratio HSDT (Helius Medical Technologies Inc.)|Short-Term Debt to Capital PASG|Short-Term Debt to Equity Ratio bionomics.com.au NEUP|Minerva Neurosciences, Inc. - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Coefficient Athira Pharma Inc (ATHA)|Addex Therapeutics, Ltd. - Short-Term Debt to Capital|Short-Term Indebtedness to Equity Alzamend Neuro, Inc. (ALZN)|cyclerion.com (CYCN) - Short-Term Debt to Equity|Protagenic Therapeutics, Inc. - Ratio of Short-Term Indebtedness to Capital|KTTA (Pasithea Therapeutics Corp) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Cortigent Medical (CRGT)|Short-Term Debt to Capital ATXI|BCLI - Current Liabilities to Capital|Short-Term Debt to Equity Cara Therapeutics, Inc. CARA|CHRO: Short-Term Debt to Capital Ratio|Eliem - Short-Term Debt to Capital|Current Liabilities to Capital Intra-Cellular Therapies|LBPH (Longboard Pharma) - Short-Term Debt to Equity Ratio|Marinus Pharma (MRNS) - Short-Term Debt to Capital|Short-Term Debt to Equity NKGen Biotech, Inc.|NRBO: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Sage Therapeutics (SAGE)|SNPX - Current Liabilities to Capital|Short-Term Debt to Capital TRVN (Trevena, Inc)|Short-Term Indebtedness to Equity Vigil Neuroscience Inc.|WENA - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital CERE (cerevel.com)